language_icon
EN
HI

Gland Pharma Share price

GLAND

1892.3

26.80 (-1.40%)
NSE
BSE
Last updated on 12 May, 2026 | 11:56 IST
Today's High

1928.00

Today's Low

1884.80

52 Week Low

1384.40

52 Week High

2131.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Gland Pharma Chart

Gland Pharma Share Key Metrics

Volume
43665.00
Market Cap
31618.41 CR
LTQ@LTP
57@1892.30
ATP
1898.09
Var Margin
15.17 %
Circuit Range
1535.3-2302.9
Delivery %
35.84 %
Value
8.29 CR
ASM/GSM
No
Market Lot
1

Summary

Gland Pharma share price stands at ₹1892.3 at 12 May, 2026 | 11:56. The stock Gland Pharma intraday movement has stayed between ₹1884.80 and ₹1928.00, while on a 52-week basis it has fluctuated from ₹1384.40 to ₹2131.00.
In terms of trading activity, Gland Pharma has recorded a volume of 43665 shares. The Gland Pharma has a market cap of ₹164756423. The stock’s Average Traded Price (ATP) stands at ₹189809, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 57, 189230.
The Gland Pharma operates within a circuit range of ₹1535.3-2302.9 – ₹1535.3-2302.9, with a Value of ₹8.29 CR. The Delivery Percentage for the day is 35.84%. Additionally, Gland Pharma currently falls under the No framework, and trades with a market lot size of 1.

Gland Pharma Fundamentals

View More
P/E Ratio

37.04

P/B Ratio

3.19

Div. Yield

0.95

Sector P/E

68.46

Sector P/B

3.55

Sec. Div. Yield

0.57

Gland Pharma Resistance and Support

Pivot 1917.17

Resistance

First Resistance

1955.64

Second Resistance

1992.17

Third Resistance

2030.64

Support

First Support

1880.64

Second Support

1842.17

Third Support

1805.64

Gland Pharma Shareholding Pattern

View More
  • 2024-25
  • 2025-26
  • 2026-27
  • 2023-24
  • 2022-23
  • 2021-22
  • 2020-21
Total Promoters
Segment
Percent

Total Promoters

58.36%

Mutual Fund

9.73%

Insurance

0.45%

Foreign Institutional Investors

12.73%

Domestic Institutional Investors

0.63%

Retail

18.1%

Others

0%

Total Promoters
DEC '20
58.36%

Gland Pharma Corporate Actions

DateAgenda
2026-05-15Audited Results & Final Dividend
2026-01-28Quarterly Results
2025-11-03Quarterly Results
2025-08-05Quarterly Results
2025-05-20Audited Results & Final Dividend
2025-02-03Quarterly Results

Gland Pharma News

Gland Pharma Limited

Gland Pharma clarified the remuneration structure for reappointed Independent Director Ms. Naina Lal Kidwai. The company will obtain annual shareholder approval via special resolution for her remuneration, which exceeds 50% of the total Non-Executive Directors' pay from FY 2026-27 to FY 2030-31.
Apr 27 2026 14:04:00

Gland Pharma Limited

Gland Pharma's Board will convene on May 15, 2026, to review and approve the audited standalone and consolidated financial results for the financial year ended March 2026. The agenda also includes a proposal for a final dividend.
Apr 21 2026 18:04:00

Gland Pharma Limited

Gland Pharma will host an earnings conference call on May 15, 2026, at 18:30 IST. The call will cover the company's financial performance and business updates for Q4 FY26 and the full fiscal year ended March 31, 2026. Transcripts and audio will be available on the company website.
Apr 21 2026 17:04:00

Gland Pharma Ltd - 543245 - Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026 And To Consider And Recommend Payment Of Final Dividend, If Any For The Financial Year Ended March 31, 2026

Gland Pharma's Board will convene on May 15, 2026, to approve financial results for Q4 & FY26 and consider a final dividend. An investor/analyst call is scheduled for the same day.
Apr 21 2026 17:04:00

Gland Pharma Ltd - 543245 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Gland Pharma initiated a postal ballot for the re-appointment of Ms. Naina Lal Kidwai as an Independent Director for a 5-year term. The resolution includes a commission of 0.25% on net profits, capped at ₹1 crore per annum, for FY2026-27 to FY2030-31.
Apr 13 2026 16:04:00

Gland Pharma Limited

Gland Pharma initiates a postal ballot to reappoint Ms. Naina Lal Kidwai as an Independent Director for a second term of five years, extending until May 2031. She will receive a commission of 0.25% on net profits, capped at ₹1 crore annually for FY27-FY31, as recommended by the Board.
Apr 13 2026 16:04:00
Read More

About Gland Pharma

NSE : 1186  
BSE : 543245  
ISIN : INE068V01023  

The Company was incorporated as ‘Gland Pharma Private Limited’ a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. Subsequently the name of the Company was changed to ‘Gland Pharma Limited’ pursuant to a special resolution passed by the shareholders of the Company on December 5 1994 and a fresh certificate of incorporation dated April 25 1995 was issued by the Registrar of Companies Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act 1956.Major events and milestones of the Company :2019- Filed Dexrazoxane for Injection the first filing with the National Medical Products Administration China and received clinical waiver2018- Received ANDA approval for Enoxaparin Sodium Injection USP for the US market- Received ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% the first Ophthalmic product approval2017- Fosun Singapore acquired 74% stake in the Company2016- Obtained USFDA approval for the facilities at Jawaharlal Nehru Pharma City Visakhapatnam- Obtained USFDA approval for the manufacturing facility at Pashamylaram- Obtained USFDA approval for the facility at the Visakhapatnam Special Economic Zone2014- Obtained USFDA approval for small volume parenteral manufacturing facility at Visakhapatnam- Commissioned the Pashamylaram Unit-II manufacturing facility- Received the ‘Certificate of GMP Compliance of a Manufacturer’ from MHRA (UK) for manufacturing facility at Dundigal- Capital infusion of US$ 100 million into the Company pursuant to private equity investment aggregating to approximately US$ 200 million with KKR Floorline Investment Pte Ltd2012- Received the ‘Certificate of GMP Compliance of a Manufacturer’ from BGV Hamburg (Germany) for the manufacturing facility at Dundigal2010- Launched Heparin Sodium Injection in the US2007- Capital infusion of approximately Rs.1000 million into the Company pursuant to private equity investment aggregating to approximately Rs.1200 million with EILSF Co-Invest I LLC2004 - 2005- Launch of Enoxaparin Sodium Injection (Cutenox) in India and Rest of the world markets2003- Received USFDA approval for the manufacturing facility at Dundigal2000- Set up the in-house R&D facility at Dundigal Hyderabad1978- Incorporation of the Company by P.V.N. RajuAwards accreditations and recognitions received by the Company :2019- The Company was awarded the “Best Exporter” by the Hyderabad Customs- The Company was awarded the “Express Pharma Excellence Awards 2019” under the turnover base Rs. 500 – 2000 crore category organized by the Express Pharma and Optel Group- The Company was awarded the “Telangana Best Employer Brand Award” at the 14th Employer Branding Awards organised by the Employer Branding Institute India2018- The Company was awarded the “Top Exporter” by the Hyderabad Customs Customs and Central Excise Government of India- The Company was awarded the “Outstanding Export Performance Award” under Formulations Silver Star category by Pharmaceuticals Export Promotion Council of India2017- The Company was awarded the “Excellence in Export Performance” at the Federation of Telangana and Andhra Pradesh Chambers of Commerce and Industry instituted by Surana Group of Industries Secunderabad- The Company was awarded the “Outstanding Export Performance Award” under Formulations Fast Growing -1 category by Pharmaceuticals Export Promotion Council of India2016- The Company was awarded the “Top Exporter/Importer” by the Hyderabad Customs Commissionerate Customs and Central Excise Government of India2014- The Company was awarded the “Outstanding Exports Performance Award” under the Regional (America and Oceania) category by Pharmaceuticals Export Promotion Council of India- The Company received the BS OHSAS 18001:2007 certifying the occupational health and safety management system of the manufacturing facility at Dundigal- The Company received ISO 14001:2015 certifying the environmental management system of the manufacturing facility at Dundigal- The Company received ISO 9001:2015 certifying the quality management system of manufacturing facility at Dundigal

Read More

Gland Pharma Management

NamePosition
Sampath Kumar PallerlamudiCompany Secretary & Compliance Officer
Srinivas SaduChairman
View More

Gland Pharma FAQs

The Buying Price of Gland Pharma share is 1892.3 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Gland Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Gland Pharma, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Gland Pharma shares is 37.04. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Gland Pharma shares is 3.19. Useful to assess the stock's value relative to its book value.

To assess Gland Pharma’s valuation compare Sector P/E, P/B which are 68.46 & 3.55 with sector averages, along with growth rates and financial metrics.

The Market Cap of Gland Pharma is 31618.41 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Gland Pharma share price is 2131.00 & 1384.40. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Gland Pharma belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost